Cargando…

1387. Impact of Cytomegalovirus Prophylaxis on Healthcare Resource Use and Costs among Kidney Transplant Recipients: A United States Renal Data System-Medicare Linked Database Study

BACKGROUND: Cytomegalovirus (CMV) management requires a balance between reducing the risk of CMV infection and avoiding anti-viral toxicities. Limited information is available on the impact of CMV prophylaxis on the healthcare resource use (HCRU) and costs among adult kidney transplant recipients (K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raval, Amit D, Ganz, Michael, Saravanan, Priya, Tang, Yuexin, Santos, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644577/ http://dx.doi.org/10.1093/ofid/ofab466.1579

Ejemplares similares

1378. Impact of Cytomegalovirus Prophylaxis on Clinical Outcomes in Kidney Transplantation: A United States Renal Data System-Medicare Linked Database Study
por: Raval, Amit D, et al.
Publicado: (2021)

Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
por: Raval, Amit D., et al.
Publicado: (2022)

Expression of Concern: Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
Publicado: (2023)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

PMM - 18 mars 1387
por: Daneels, A
Publicado: (1987)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
por: Huang, Glen, et al.
Publicado: (2020)

210. Neutropenia and Associated Infectious Complications Among Kidney Transplant Recipients Receiving Valganciclovir Prophylaxis in the United States: An Administrative Claims Database Study
por: Turzhitsky, Vladimir, et al.
Publicado: (2022)

1387. Current practices in the diagnosis and treatment of varicella infections in the United States
por: Fergie, Jaime, et al.
Publicado: (2020)

Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients
por: Park, Woo Yeong, et al.
Publicado: (2020)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
por: Chen, Zide, et al.
Publicado: (2018)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Healthcare disparity and its associations with cytomegalovirus disease in pediatric liver transplant recipients in South Africa
por: Walabh, Priya, et al.
Publicado: (2022)

Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G
por: Lee, Angela J., et al.
Publicado: (2019)

Fungal diversity notes 1387–1511: taxonomic and phylogenetic contributions on genera and species of fungal taxa
por: Boonmee, Saranyaphat, et al.
Publicado: (2021)

1387. Prevalence and Risk Factors for Bacterial Resistance in Diabetic Foot Infections at a Hospital in Nicaragua.
por: Sandoval-Rojas, Kevin A, et al.
Publicado: (2022)

Molecular Detection and Genotyping of Human Cytomegalovirus in Kidney Transplant Recipients under Ganciclovir Prophylaxis in Iran
por: Behnezhad, Farzane, et al.
Publicado: (2022)

1706. Association between Cytomegalovirus Infection/Disease and Morbidity and Mortality in Kidney Transplantation: A Systematic Literature Review of Observational Studies
por: Raval, Amit D, et al.
Publicado: (2020)

Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson’s Disease
por: Song, Yan, et al.
Publicado: (2023)

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
por: Sepassi, Aryana, et al.
Publicado: (2023)

Incident colorectal cancer screening and associated healthcare resource utilization and Medicare cost among Medicare beneficiaries aged 66–75 years in 2016–2018
por: Li, Suying, et al.
Publicado: (2022)

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis
por: Amin, Alpesh, et al.
Publicado: (2022)

Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
por: Zhao, Yang, et al.
Publicado: (2008)

Prevalence and Distribution of HPV Genotypes in 1387 Women with Cervical Intraepithelial Neoplasia 2/3 in Shanxi Province, China
por: Wang, Zhilian, et al.
Publicado: (2018)

P1387: MONITORING OF DONOR CHIMERISM ON RED BLOOD CELLS ANTIGENS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Yovdiy, A., et al.
Publicado: (2022)

Cytomegalovirus infections in the blood recipient.
por: Nankervis, G. A.
Publicado: (1976)

Cytomegalovirus infection in transplant recipients
por: Azevedo*, Luiz Sergio, et al.
Publicado: (2015)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
por: Selvey, Linda A., et al.
Publicado: (2017)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

CR de la reunion du 3 Fevrier 1387 au sujet du dévoloppement du nouveau GFA
por: Burla, P
Publicado: (1987)

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
por: Khurana, Mark P, et al.
Publicado: (2019)

1747. Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients
por: Watts, Corey, et al.
Publicado: (2019)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v605lfrqss1eur9vasba016gfm